Biocon Ltd. and partner Mylan NV have ended 2017 with another regulatory win, after Brazil’s Anvisa approved their biosimilar Herceptin (trastuzumab).
The approval, which marks the arrival of the first biosimilar trastuzumab in the Latin American nation, came through Libbs Farmaceutica, the duo’s local partner in Brazil. Earlier this month the US FDA had approved the first biosimilar to Herceptin from Mylan and Biocon
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?